81vette
1 year ago
$50 million,partnership with Department of Defenseโs,Defense Threat Reduction Agency (โDTRAโ) to investigate ACG-701 as a potential medical countermeasure for melioidosis, a life-threatening infection caused by the B. pseudomallei pathogen. This program is centered around a Phase 2 trial, the TERRA study (NCT05105035), which is a randomized double-blind, placebo-controlled trial conducted in hospitalized melioidosis patients.
81vette
1 year ago
2.62M float,3.66M o/s,short .02M,book pps $3.23,cash/share $1.25,target $17.00,sales $4.86M,26 employees,insiders 8.6%,institutions 5.6%,volitility 16%-23%,shares available to short dropped 500% this morning,(still 1000 since 8am) <great sign of rebound,could go to ZERO BORROW soon,above ave buying vol.,accumulation started fri.